Human Papillomavirus Infections is an indication for drug development with over 100 pipeline drugs currently active. According to GlobalData, preregistered drugs for Human Papillomavirus Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Human Papillomavirus Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Human Papillomavirus Infections overview
Human Papillomavirus (HPV) infections are common sexually transmitted infections caused by the HPV virus. There exist over 100 types, some leading to genital warts, while others increase the risk of various cancers, including cervical, anal, and throat cancers. Often asymptomatic, HPV can spread through sexual contact, including skin-to-skin contact. Vaccines effectively prevent many high-risk HPV types, reducing infection and cancer risk. Regular screenings, such as Pap tests for cervical cancer, aid in early detection. Treatment focuses on managing symptoms; however, no cure exists for the virus itself. Safe sex practices and vaccination are key in preventing HPV transmission.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Human Papillomavirus Infections, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
